Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
76,302
Employees76,302
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
76,302
Employees76,302

NVO Key Statistics

Market cap
212.72B
Market cap212.72B
Price-Earnings ratio
14.09
Price-Earnings ratio14.09
Dividend yield
2.54%
Dividend yield2.54%
Average volume
24.20M
Average volume24.20M
High today
$48.27
High today$48.27
Low today
$47.20
Low today$47.20
Open price
$47.60
Open price$47.60
Volume
17.04M
Volume17.04M
52 Week high
$112.52
52 Week high$112.52
52 Week low
$45.05
52 Week low$45.05

Stock Snapshot

With a market cap of 212.72B, Novo Nordisk(NVO) trades at $47.46. The stock has a price-to-earnings ratio of 14.09 and currently yields dividends of 2.5%.

On 2025-11-18, Novo Nordisk(NVO) stock moved within a range of $47.20 to $48.27. With shares now at $47.46, the stock is trading +0.6% above its intraday low and -1.7% below the session's peak.

Trading activity shows a volume of 17.04M, compared to an average daily volume of 24.2M.

Over the past 52 weeks, Novo Nordisk(NVO) stock has traded between a high of $112.52 and a low of $45.05.

Over the past 52 weeks, Novo Nordisk(NVO) stock has traded between a high of $112.52 and a low of $45.05.

NVO News

The Motley Fool 1h
Why Big Pharma Won't Quit the Diet. Who Will Win the Next Weight Loss Battle?

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish line. Chances are you know someone on...

Why Big Pharma Won't Quit the Diet. Who Will Win the Next Weight Loss Battle?
Cheddar 3h
Novo Nordisk Slashes Wegovy & Ozempic Prices

Novo Nordisk will cut the direct-to-consumer prices of Wegovy and Ozempic, bringing monthly costs for many cash-paying patients down to $349....

Novo Nordisk Slashes Wegovy & Ozempic Prices
TipRanks 12h
Sell Rating for Hims & Hers Health Amid Pricing Pressures from Novo Nordisk’s GLP-1 Products

Analyst Allen Lutz of Bank of America Securities maintained a Sell rating on Hims & Hers Health, retaining the price target of $32.00. Meet Your ETF AI Analyst...

Analyst ratings

59%

of 32 ratings
Buy
59.4%
Hold
31.3%
Sell
9.4%

More NVO News

TipRanks 1d
Novo Nordisk Announces Insider Share Transactions

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...

Benzinga 1d
Novo Nordisk Leans Into Affordability Amid Rising Competition

Novo Nordisk A/S (NYSE:NVO) announced on Monday that Wegovy (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic are now available at a limited-time price of...

Novo Nordisk Leans Into Affordability Amid Rising Competition
TipRanks 1d
Eli Lilly Stock Falls as Rival Novo Nordisk Cuts Weight-Loss Drug Prices

The stock of pharmaceutical company Eli Lilly (LLY) is down 1% on Nov. 17 after news broke that rival Novo Nordisk (NVO) has lowered the direct-to-consumer pric...

Benzinga 1d
Novo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control

Newly installed Chairperson Lars Rebien Sorensen signaled a rapid shift in governance and strategic direction at Novo Nordisk A/S (NYSE:NVO) , saying he intends...

Novo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control
Investor's Business Daily 1d
How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration

Novo Nordisk (NVO) undercut Eli Lilly (LLY) and the Trump administration on Monday, slashing the cash price of its drugs Wegovy and Ozempic to just $349 a month...

How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration
TipRanks 1d
GoodRx announces weight loss telemedicine subscription, Novo Nordisk pact

GoodRx (GDRX) announced two major initiatives to make FDA-approved GLP-1 medications more widely available. First, the launch of GoodRx for Weight Loss, a telem...

Nasdaq 1d
Warren Buffett Detailed Fundamental Analysis - NVO

Below is Validea's guru fundamental report for NOVO NORDISK A/S (ADR) (NVO). Of the 22 guru strategies we follow, NVO rates highest using our Patient Investor m...

Warren Buffett Detailed Fundamental Analysis - NVO
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.